Skip to main content
Equibles
EYPT logo

EYPT · EyePoint, Inc. · Documents

Track EYPT — free

Use EYPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EYPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.40 0.00 (-1.23%) At close · Nov 4 Play latest call Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$34.05M
Shares
86.21M
Volume · Nov 4 3.07M Avg daily vol (3M) 9.03M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $31.37M down 27.5% 10-K filed Mar 5, 2026 Quarterly report FY2026 Q2 Revenue $507K down 90.5% 10-Q filed Aug 5, 2026 Latest results Financial results 8-K filed Oct 19, 2026 Earnings call Q1 2026 earnings call Held May 6, 2026
2026
Oct 19
Current report 8-K Events of Oct 17
Financial results, Exit or restructuring costs, Other events

EyePoint announced a strategic prioritization after its Phase 3 LUCIA trial of DURAVYU in wet AMD missed its primary endpoint, cutting its workforce by approximately 53% and incurring about $9 million in severance charges.

Oct 19
Current report 8-K
Other events

EyePoint announced LUCIA Phase 3 topline data showing DURAVYU missed its primary BCVA non-inferiority endpoint in wet AMD (+2.5 vs aflibercept +6.1 letters), though it met key secondary endpoints including a 38% reduction in treatment burden. DME Phase 3 topline data is expected in Q4 2027.

Sep 10
Current report 8-K
Other events AI summary on its way
Aug 17
Current report 8-K
Other events AI summary on its way
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $507K ▼ 90.5% Net loss $94.47M Diluted EPS -$1.09
Jul 30
Current report 8-K
Other events AI summary on its way
May 14
Current report 8-K
Other events AI summary on its way
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $696K ▼ 97.2% Net loss $84.83M Diluted EPS -$0.99
Apr 27
Proxy statement DEF 14A Meeting Jun 18, 2026
Proxy statement AI summary on its way
Apr 13
Current report 8-K
Other events AI summary on its way
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $31.37M ▼ 27.5% Net loss $231.96M Diluted EPS -$3.17
Mar 2
Current report 8-K Events of Feb 26
Other events AI summary on its way
2025
Showing 1–50 of 216 documents
Key facts CIK 1314102 CUSIP 30233G209 13F (30d) 35 filings 34 filers Visit website Investor relations